Pharmacogenomics of Drug Safety in Multiple Sclerosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 90
Summary
- Conditions
- Multiple Sclerosis
- Type
- Observational
- Design
- Observational Model: Case-ControlTime Perspective: Retrospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PURPOSE: To investigate whether genotypic differences can be identified between MS patients who develop liver injury compared to those who do not develop injury in response to beta-interferon therapy. OBJECTIVE: To determine whether elevated liver enzyme tests (ALT > 5 times the upper limit of norma...
PURPOSE: To investigate whether genotypic differences can be identified between MS patients who develop liver injury compared to those who do not develop injury in response to beta-interferon therapy. OBJECTIVE: To determine whether elevated liver enzyme tests (ALT > 5 times the upper limit of normal) in response to beta-interferon therapy in MS patients is associated with genetic polymorphisms. METHOD OF RECRUITMENT: Patients will be identified through a clinic database and chart reviews. An introductory letter will be mailed to potential participants, inviting them to volunteer. A follow-up phone call will be made to determine interest and consent into study. PROCEDURES: Saliva will be collected for genetic analyses and a questionnaire will be administered
Tracking Information
- NCT #
- NCT01118130
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Canada Foundation for Innovation
- Genome Canada
- British Columbia Clinical Genomics Network
- Investigators
- Principal Investigator: Bruce Carleton University of British Columbia Study Director: Michael Hayden University of British Columbia Study Director: Helen Tremlett University of British Columbia Study Director: Anthony Traboulsee University of British Columbia
Get Well Soon